BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

December 3, 2012 8:00 AM UTC

Actelion Ltd. (SIX:ATLN) was up CHF0.96 to CHF45.90 last week after EMA accepted for review an MAA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). The company submitted an NDA to FDA in October.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.60 to $22.36 last week, even as partner Merck & Co. Inc. (NYSE:MRK) withdrew an MAA in the EU for ridaforolimus as maintenance therapy for patients with soft tissue sarcoma or primary malignant bone tumor. According to the pharma, CHMP said based on a "provisional view" that the data were "not sufficient" for approval. Merck has exclusive, worldwide rights from Ariad, which has co-promotion rights in the U.S...